The Biochemical Basis of Arsenical–Diamidine Crossresistance in African Trypanosomes
- 1 April 1999
- journal article
- review article
- Published by Elsevier BV in Parasitology Today
- Vol. 15 (4), 136-140
- https://doi.org/10.1016/s0169-4758(99)01414-3
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sicknessTransactions of the Royal Society of Tropical Medicine and Hygiene, 1995
- Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solutionAntimicrobial Agents and Chemotherapy, 1994
- The Treatment of Human African TrypanosomiasisAdvances in Parasitology, 1994
- Resistance to clinical drugs in African trypanosomesParasitology Today, 1993
- The interaction of arsenical drugs with dihydrolipoamide and dihydrolipoamide dehydrogenase from arsenical resistant and sensitive strains of Trypanosoma brucei bruceiMolecular and Biochemical Parasitology, 1992
- Perspectives in research on and control of African trypanosomiasisPathogens and Global Health, 1991
- Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesienseAntimicrobial Agents and Chemotherapy, 1990
- Trypanothione is the primary target for arsenical drugs against African trypanosomes.Proceedings of the National Academy of Sciences, 1989
- Effects of various metabolic conditions and of the trivalent arsenical melarsen oxide on the intracellular levels of fructose 2,6‐bisphosphate and of glycolytic intermediates in Trypanosoma bruceiEuropean Journal of Biochemistry, 1987
- Mel B in the Treatment of Human Trypanosomiasis 1,2The American Journal of Tropical Medicine and Hygiene, 1949